Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome

J Dermatol. 2021 Jan;48(1):92-95. doi: 10.1111/1346-8138.15562. Epub 2020 Nov 12.

Abstract

Drug-induced hypersensitivity syndrome (DIHS) is a type of severe drug adverse reaction with high morbidity and mortality. DIHS patients have been reported to subsequently develop autoimmune disease, which may be followed by end-organ decompensation. We report a 47-year-old woman who presented with fever, generalized maculopapular eruption, facial edema and eosinophilia with liver function impairment after taking celecoxib and sulfasalazine for 1 month. The patient was diagnosed with definite DIHS. The patient was treated with immunosuppressants including systemic corticosteroid for approximately 1.5 years due to recurrent episodes. Reactivation of human herpesvirus 6 and possible reactivation of cytomegalovirus were detected. Generalized hypopigmentation of the skin and leukotrichia were noted 4 months after the onset of DIHS. Histopathological examination confirmed the diagnosis of vitiligo. Some spontaneous repigmentation was noted 4 years after DIHS without specific treatment. Further immunoserology study showed elevated plasma C-X-C motif chemokine 10 level, which is related to vitiligo activity, in our patient. The occurrence of widespread vitiligo after DIHS is an extremely rare condition. This case provides an important reminder for physicians to monitor such severe complications after DIHS.

Keywords: autoimmune sequelae; drug-induced hypersensitivity syndrome; human herpesvirus 6; sulfasalazine; vitiligo.

Publication types

  • Case Reports

MeSH terms

  • Drug Hypersensitivity Syndrome* / diagnosis
  • Drug Hypersensitivity Syndrome* / etiology
  • Drug Hypersensitivity*
  • Eosinophilia*
  • Female
  • Humans
  • Hypopigmentation*
  • Middle Aged
  • Pharmaceutical Preparations*
  • Vitiligo* / chemically induced
  • Vitiligo* / diagnosis

Substances

  • Pharmaceutical Preparations